ALPHA PRO TECH LTD — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ALPHA PRO TECH LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.54M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $22.93M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $22.83M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $21.68M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $25.30M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $50.48M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $16.97M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $17.71M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $17.45M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $16.98M | Mar 12, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.53M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $3.93M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.19M | Mar 12, 2025 |
| FY2023 | Sep 30, 2023 | $1.43M | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | $1.15M | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | $552.0K | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $3.28M | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | $503.0K | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | $693.0K | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | $1.52M | Mar 13, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.84M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $3.45M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.13M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.65M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $7.93M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $31.58M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.02M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $3.87M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $2.93M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.67M | Mar 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.77M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.61M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $17.77M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $16.22M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $16.55M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $18.17M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $13.35M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $13.31M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $13.96M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $12.77M | Mar 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.70M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $8.46M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.28M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($480.0K) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $18.27M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.10M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $2.00M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $4.01M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $6.83M | Mar 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $639.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $3.81M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $792.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $492.0K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.52M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.14M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.30M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $606.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.22M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $267.0K | Mar 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.13M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $73.74M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $68.76M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $64.80M | Mar 13, 2024 |
| FY2022 | Sep 30, 2022 | $65.08M | Mar 16, 2023 |
| FY2022 | Jun 30, 2022 | $66.69M | Mar 16, 2023 |
| FY2022 | Mar 31, 2022 | $66.75B | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $67.02M | Mar 16, 2023 |
| FY2022 | Sep 30, 2021 | $67.03M | Mar 16, 2023 |
| FY2022 | Jun 30, 2021 | $66.80M | Mar 16, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.65M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $11.51M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $7.20M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.05M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.27M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $9.13M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.86M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $2.06M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $2.80M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.27M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.48M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $62.23M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $61.57M | Mar 11, 2026 |
| FY2023 | Sep 30, 2023 | $61.39M | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | $61.12M | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | $60.99M | Mar 13, 2024 |
| FY2024 | Dec 31, 2022 | $60.76M | Mar 12, 2025 |
| FY2023 | Sep 30, 2022 | $61.26M | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | $61.95M | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | $62.42M | Mar 13, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $55.0K | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $55.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $55.0K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $55.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $55.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $55.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $55.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $55.0K | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $55.0K | Mar 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.50M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $47.26M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $46.55M | Mar 12, 2025 |
| FY2023 | Sep 30, 2023 | $46.21M | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | $45.47M | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | $45.03M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $45.03M | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | $45.16M | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | $45.41M | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | $45.36M | Mar 13, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.99M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.64M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $20.38M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $16.29M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $16.31M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $23.29M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $6.55M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $7.01M | Mar 10, 2020 |
| FY2019 | Dec 31, 2017 | $8.76M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $9.46M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 2 | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 12, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 1 | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 12, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.13M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 10.82M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 11.42M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 12.23M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | 13.12M | Mar 13, 2024 |
| FY2021 | Dec 31, 2020 | 13.42M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 12.89M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 13.50M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 14.29M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 15.41M | Mar 12, 2018 |